

Global Cancer Biomarker Market - 2022

<https://marketpublishers.com/r/G0ECD5F83EA5EN.html>

Date: September 2025

Pages: 218

Price: US\$ 2,999.00 (Single User License)

ID: G0ECD5F83EA5EN

Abstracts

The Global Cancer Biomarker Market was valued at USD 13.2 billion in 2022 and is anticipated to reach by , at a CAGR of 0.123 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Cancer Biomarker Market.

This report delivers a comprehensive overview of the Global Cancer Biomarker Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Cancer Biomarker Market. The Global Cancer Biomarker Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–.

Global Cancer Biomarker Market Scope:

By Cancer Indication

Sarcoma

Colorectal Cancer

Cervical Cancer

Lung Cancer

Breast Cancer

By Biomarker Type

PSA

HER-2

EGFR

KRAS

Others

By Profiling Technology

OMICS Technologies

Cytogenetics

Immunoassays

Imaging Technologies

Bioinformatics

By End User

Hospitals

Academic and Cancer Research Institutes

Ambulatory Surgical Centers

Diagnostic Laboratories

Key Players

F. Hoffmann-La Roche Ltd

Thermo Fisher Scientific, Inc.

QIAGEN N.V.

Illumina, Inc.

Bio-Rad Laboratories, Inc.

Abbott Laboratories

bioMerieux SA

Enzo Biochem, Inc.

Merck Millipore

Micron Technology(LIST NOT EXHAUSTIVE)

Major Highlights

This report delivers a comprehensive overview of the Global Cancer Biomarker Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Cancer Biomarker Market. The Global Cancer Biomarker Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for

the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client,

gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Cancer Indication
- 3.2. Snippet by Biomarker Type
- 3.3. Snippet by Profiling Technology
- 3.4. Snippet by End User
- 3.5. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Growing Prevalence of Cancer
 - 4.1.1.2. Increase in Strategic Developments
 - 4.1.2. Restraints
 - 4.1.2.1. High Cost of Biomarkers
 - 4.1.3. Opportunity
 - 4.1.3.1. Development of Personalized Medicine
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis

6. COVID-19 ANALYSIS

- 6.1. Analysis of COVID-19

- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

7. BY CANCER INDICATION

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
 - 7.1.2. Market Attractiveness Index, By Cancer Indication
- 7.2. Sarcoma*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Colorectal Cancer
- 7.4. Cervical Cancer
- 7.5. Lung Cancer
- 7.6. Breast Cancer

8. BY BIOMARKER TYPE

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
 - 8.1.2. Market Attractiveness Index, By Biomarker Type
- 8.2. PSA*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. HER-2
- 8.4. EGFR
- 8.5. KRAS
- 8.6. Others

9. BY PROFILING TECHNOLOGY

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology

- 9.1.2. Market Attractiveness Index, By Profiling Technology
- 9.2. OMICS Technologies*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Cytogenetics
- 9.4. Immunoassays
- 9.5. Imaging Technologies
- 9.6. Bioinformatics

10. BY END USER

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 10.1.2. Market Attractiveness Index, By End User
- 10.2. Hospitals*
 - 10.2.1. Introduction
 - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Academic and Cancer Research Institutes
- 10.4. Ambulatory Surgical Centers
- 10.5. Diagnostic Laboratories

11. BY REGION

- 11.1. Introduction
 - 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
 - 11.2.1. Introduction
 - 11.2.2. Key Region-Specific Dynamics
 - 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
 - 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
 - 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
 - 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.2.7.1. U.S.
 - 11.2.7.2. Canada
 - 11.2.7.3. Mexico
- 11.3. Europe
 - 11.3.1. Introduction

- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.3.7.1. Germany
 - 11.3.7.2. U.K.
 - 11.3.7.3. France
 - 11.3.7.4. Spain
 - 11.3.7.5. Italy
 - 11.3.7.6. Rest of Europe
- 11.4. South America
 - 11.4.1. Introduction
 - 11.4.2. Key Region-Specific Dynamics
 - 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
 - 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
 - 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
 - 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.4.7.1. Brazil
 - 11.4.7.2. Argentina
 - 11.4.7.3. Rest of South America
- 11.5. Asia-Pacific
 - 11.5.1. Introduction
 - 11.5.2. Key Region-Specific Dynamics
 - 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
 - 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
 - 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
 - 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.5.7.1. China
 - 11.5.7.2. India
 - 11.5.7.3. Japan
 - 11.5.7.4. Australia
 - 11.5.7.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
 - 11.6.1. Introduction
 - 11.6.2. Key Region-Specific Dynamics

- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. COMPETITIVE LANDSCAPE

- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis

13. COMPANY PROFILES

- 13.1. F. Hoffmann-La Roche Ltd*
 - 13.1.1. Company Overview
 - 13.1.2. Product Portfolio and Description
 - 13.1.3. Financial Overview
 - 13.1.4. Key Developments
- 13.2. Thermo Fisher Scientific, Inc.
- 13.3. QIAGEN N.V.
- 13.4. Illumina, Inc.
- 13.5. Bio-Rad Laboratories, Inc.
- 13.6. Abbott Laboratories
- 13.7. bioMérieux SA
- 13.8. Enzo Biochem, Inc.
- 13.9. Merck Millipore
- 13.10. Micron Technology(*LIST NOT EXHAUSTIVE)

14. APPENDIX

- 14.1. About Us and Services
- 14.2. Contact Us

I would like to order

Product name: Global Cancer Biomarker Market - 2022

Product link: <https://marketpublishers.com/r/G0ECD5F83EA5EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0ECD5F83EA5EN.html>